A public offering of common stock and common warrants has been priced by OpGen in hopes of raising $10 million. Net proceeds will be used to support general corporate functions, particularly the repayment of all outstanding bridge financing notes and the development of a one- to three-hour antibiotic resistance diagnostic product.
Public offering could bring in $10M for OpGen
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.